Antiviral Research

Interaction of -L-2&unknown;,3&unknown;-dideoxy-2&unknown;,3&unknown;-didehydro-5-fluorocytidine 5&unknown;-triphosphate with HIV reverse transcriptase and human DNA polymerases: implication for HIV drug design
pp. 39-39(1)
Authors: Kukhanova M.; Li X.; Chen S.; King I.; Doyle T.; Prusoff W.; Cheng Y.C.

Synthesis and In Vitro Anti-HIV-1 Activity of D-D4FC Analogs
pp. 39-39(1)
Authors: Shi J.; Liotta D.C.; Schinazi R.F.

L-purine dideoxynucleotide prodrugs as inhibitors of HIV replication
pp. 40-40(1)
Authors: Imbach J.-L.; Gosselin G.; Mathe C.; Pierra C.; Boudou V.; Faraj A.; Cretton-Scott E.; Placidi L.; Schinazi R.F.; Sommadossi J.-P.

PETT-4, New Potent Allosteric Inhibitors of HIV-1 Reverse Transcriptase
pp. 40-40(1)
Authors: Oberg B.; &unknown;9hgren C.; Benthin R.; Bottiger D.; Classon B.; Cox S.; Engelhardt P.; Ekelof K.; Harmenberg J.; Hogberg M.; Johansson N.G.; Kangasmetsa J.; Lind P.; Noreen R.; Pelcman M.; Rydergard C.; Sahlberg B.-L.; Sahlberg C.; Uberla K.; Vrang L.; Zhang H.; Zhou X.-X.

Crystal Structures of the PETT Compounds MSC-204 and MSH-372 in Complex with Human Immuno-deficiency Virus Reverse Transcriptase
pp. 40-40(1)
Authors: Unge T.; Carlsson F.; Fridborg K.; Hogberg M.; Johansson N.G.; Lowgren S.; Sahlberg C.

Involvement of an Active Efflux Pump in the Cellular Resistance of Anti-Retroviral Nucleoside Analogs
pp. 40-40(1)
Authors: Fridland A.; PaiBir S.; Srinivas R.; Connelly M.; Robbins B.; Pinkerton F.; Schuetz J.

Comparison of the Antiviral Activity of Several Acyclic Nucleoside Phosphonate Derivatives in Feline Immunodeficiency Virus-Infected Cats
pp. 41-41(1)
Authors: Hartmann K.; Kuffer M.; Wilhelm N.; Aigner C.; Goldberg M.; Lederer E.; Goebel F.-D.; Erfle V.; De Clercq E.; Balzarini J.

Can the Bottleneck in AZT Activation be Efficiently Circumvented by Transfection of HIV-Susceptible Cells with Murine Thymidylate Kinase or Herpetic Thymidine Kinase?
pp. 41-41(1)
Authors: Balzarini J.; Degreve B.; De Clercq E.

Genotypic Characterization of HIV-1 Isolated from AIDS Patients After Prolonged Therapy with Adefovir Dipivoxil (Preveon^TM) Added to Existing Regimens
pp. 41-41(1)
Authors: Cherrington J.M.; Lamy P.D.; Margot N.A.; Mulato A.S.

A Novel Potent Anti-VZV Pyrimidine Nucleoside AV-100: Synthesis, Antiherpetic Activity and Pharmacokinetics
pp. 42-42(1)
Authors: Tsuji T.; Onishi T.; Mukai C.; Nakagawa R.; Sekiyama T.; Aoki M.; Suzuki K.; Nakazawa H.; Ono N.; Ohmura Y.; Iwayama S.; Okunishi M.

Aminothiazolyl-Phenyl-Based Inhibitors of HSV Helicase-Primase: A Novel Class of Orally Active Antiherpetic Agents
pp. 42-42(1)
Authors: Liuzzi M.; Crute J.J.; Grygon C.A.; Hargrave K.D.; Simoneau B.; Faucher A.-M.; Bolger G.; Duan J.; Kibler P.; Cordingley M.G.

T157602, A 2-Amino Thiazole Inhibits HSV Replication by Interacting with the UL5 Component of the UL5/8/52 Helicase Primase Complex
pp. 43-43(1)
Authors: Spector F.C.; Liang L.; Giordano H.; Sivaraja M.; Peterson M.G.

Complementation of a thymidine kinase deficient mutant of herpes simplex virus type 1 by the parent wild type virus in a zosteriform model of herpes virus infection in mice
pp. 43-43(1)
Authors: Collins P.; Sowa M.; Fenton R.; Watts P.; Darby G.

HSV Latency Detected In Neurons by Means of the -gal Reporter Gene in Ganglia from Mice Treated with Famciclovir or Valaciclovir
pp. 43-43(1)
Authors: Field H.J.; Efstathiou S.; Thackray A.M.

Assessment of the Relationship Between the Skin Target Site Free Drug Concentration (C*) and the In vivo Efficacy for Bromovinyldeoxyuridine and Acyclovir Formulations in the Treatment of Cutaneous HSV-1 Infections in Hairless Mice
pp. 43-43(1)
Authors: Afouna M.I.; Ghanem A.-H.; Higuchi W.I.; Mehta S.C.; Kern E.R.; De Clercq E.; El-Shattawy H.

Acyclovir-resistant Herpes Simplex Virus: Preliminary Results from a National Surveillance System
pp. 44-44(1)
Authors: Reyes M.; Graber J.; Weatherall N.; Hodges-Savola C.; Reeves W.

Acyclovir-resistant Herpes Simplex Virus: Characterization of virus isolates from a nationwide surveillance system
pp. 44-44(1)
Authors: Wetherall N.T.; Hodges-Savola C.A.; Reyes M.; Graber J.M.; Lawrence W.; Nehls S.; Harden E.; Kern E.R.

The Effects of the -D and -L Enantiomers of 2&unknown;,3&unknown;-dideoxy-2&unknown;,3&unknown;-didehydro-5-fluorocytosine Triphosphate (D4FC-TP) on the Synthesis of Duck Hepatitis B Virus (DHBV) primer DNA In Vitro
pp. 45-45(1)
Authors: Staschke K.A.; Schinazi R.F.; Shi X.; Liotta D.C.; Colacino J.M.

Effect of Oral (-)--2&unknown;,3&unknown;-Dideoxy-5-Fluoro-3&unknown;-Thiacytidine [(-)-FTC] In Carriers of Infected Woodchuck Hepatitis Virus (WHV)
pp. 45-45(1)
Authors: Schinazi R.F.; Liotta D.C.; Hurwitz S.J.; Painter G.; Furman P.; Barry D.; Korba B.E.; Tennant B.C.

Decreased Replication Capacity of Duck Hepatitis B Virus Polymerase Gene Mutants Resistant to Lamivudine
pp. 46-46(1)
Authors: Aguesse-Germon S.; Pichoud C.; Trepo C.; Zoulim F.

Antiviral Activity of a Novel L-Nucleoside Analog, -L-FD4C, in the Duck HBV Infection Model
pp. 46-46(1)
Authors: Le Guerhier F.; Pichoud C.; Chevallier M.; Liu S.H.; Chen S.H.; Li X.Y.; Trepo C.; Cheng Y.C.; Zoulim F.

Utilization of transgenic mice replicating high levels of hepatitis B virus for antiviral evaluation of lamivudine
pp. 46-46(1)
Authors: Morrey J.D.; Bailey K.W.; Korba B.A.; Sidwell R.W.

The Role of Mitochondrial Deoxyribonucleoside Kinases for the Toxicity of Nucleoside Analogs
pp. 46-46(1)
Authors: Karlsson A.; Zhu C.; Johansson M.

Pharmacokinetics of -D-2&unknown;,3&unknown;-Didehydro-2&unknown;,3&unknown;-dideoxy-5-fluorocytidine (D-D4FC) in Rhesus Monkeys
pp. 47-47(1)
Authors: Ma L.; Hurwitz S.J.; Shi J.; Liotta D.C.; McClure H.M.; Schinazi R.F.

In Vivo Activity Of An Antisense Oligonucleotide Targeted Against The E1 Region Of Human Papillomavirus
pp. 47-47(1)
Authors: Lewis E.J.; Bishop J.; Chadwick J.; Cuthill S.; Dunford P.; Greenham A.K.; Gibson V.; Kelly F.; Mulqueen M.; Roberts N.A.; Szymkowski D.; Christensen N.; Kreider J.W.; Kilkuskie R.; Roberts P.

Detection of Soluble Nuclear Matrix Protein (NMP) Released from Apoptotic Nuclei of Human Papillomavirus (HPV) Positive Cell Lines Treated with Cidofovir
pp. 47-47(1)
Authors: Andrei G.; Snoeck R.; De Clercq E.

A Double-Blind, Placebo-Controlled Study of Cidofovir Gel for Human Papillomavirus (HPV)-Associated Genital Warts
pp. 47-47(1)
Authors: Snoeck R.; Bossens M.; Parent D.; Delaere B.; De Greef H.; De Clercq E.; Safrin S.; McGuire B.; Jaffe H.S.

CXCR4 is the target for the potent anti-HIV activity of the bicyclams
pp. 48-48(1)
Authors: Schols D.; Struyf S.; Wuyts A.; Van Damme J.; Bridger G.J.; Henson G.W.; De Clercq E.

The phosphoramidate approach to the intracellular delivery of free nucleotides can enhance can potency and antiviral selectivity of a variety of nucleosides
pp. 48-48(1)
Authors: McGuigan C.; Wedgwood O.; Yarnold C.; Hiouni A.; Sutton P.; Harris S.; De Clercq E.; Balzarini J.

Antiviral activity of a new class of HIV protease inhibitor: Distinct resistance and protein binding properties and bioavailability
pp. 49-49(1)
Authors: Saunders J.; Heldsinger A.; Neorr B.; McQuade T.; Gracheck S.; VanderRoest S.; Sharmeen L.

Anti-HIV Activity of Protease Inhibitors in Productively-Infected Macrophages, and Correlation with Clinical Outcome
pp. 49-49(1)
Authors: Perno C.; Newcomb F.; Aquaro S.; Davis D.; Cenci A.; Humphrey R.; Calio R.; Yarchoan R.

Blocking the entry of T-cell- and macrophage-tropic HIV-1 strains by targeting a common post-CD4-binding step
pp. 49-49(1)
Authors: Sastry K.; Nehete P.; Sarkar A.; Liu J.; Arlinghaus R.

Anti-HIV Activity in the HuPBMC SCID Mouse Model of Six Novel Nucleoside Analogs: (-)-FTC, (+/-)-FTC, D-DAPD, D-D4FC, CS-92 and CS-87
pp. 49-49(1)
Authors: Ussery M.A.; Wood O.L.; Kunder S.C.; Bacho M.A.; Broud D.D.; Papermaster S.F.; Hall B.E.; Ciavarella A.; Nielsen C.J.; Schinazi R.F.

Preclinical Pharmacokinetic Evaluation in Rat Brain and Plasma of Selected Urea-PETT Compounds
pp. 50-50(1)
Authors: Sahlberg C.; Benthin R.; Bottiger D.; Frykman K.; Hogberg M.; Sahlberg B.-L.

Predictors of Clinical Progression and Adverse Events in a Cohort of HIV-infected Patients with Advanced Immunodeficiency Started on Protease Inhibitors
pp. 50-50(1)
Authors: Raffi F.; Chene G.; Arnaud I.; Dequae L.; Chidiac C.; Coulaud J.P.; Dellamonica P.; Frottier J.; Katlama C.; Lacut J.Y.; Massip P.; May T.; Pichard E.; Ragnaud J.M.; Schmit J.L.; Vachon F.; Leport C.

Evaluation of Inhibitors of Chemokine Receptor Binding in a Cell-Based ELISA
pp. 51-51(1)
Authors: Lackman-Smith C.S.; Halliday S.H.; Buckheit R.W.

Antisense oligodeoxynucleotide inhibits HIV-1 second receptor: chemokine CC-CKR5 in macrophage-tropic COS cell line
pp. 51-51(1)
Authors: Wada A.; Kimura T.; Takai K.; Yamamoto N.; Takaku H.

SIVmnd Uses CXCR4 as Coreceptor for Entry in Human Cells
pp. 52-52(1)
Authors: Schols D.; De Clercq E.

Amino Acid Phosphoramidates of Antiviral 3-Deaza-adenosine Analogs Exhibit High Potency and Low Toxicity
pp. 52-52(1)
Authors: Wagner C.R.; McIntee E.J.; Chiang P.K.

Anti-HIV activity of new compound: prodrug of D4T
pp. 52-52(1)
Authors: Cardona V.M.F.; Ayi A.I.; Aubertin A.-M.; Guedj R.

Activity of masked 2&unknown;-3&unknown;-dideoxynucleoside-monophosphate derivatives against human immunodeficiency virus in resting macrophages
pp. 52-52(1)
Authors: Aquaro S.; Perno C.; Balzarini J.; Cardone M.; McGuigan C.; Calio R.

Studies Into The Role of The 5&unknown;-tert-Butyldimethylsilyl Group In The Anti-HIV-1 Activity of TSAO Derivatives
pp. 53-53(1)
Authors: Chamorro C.; San-Felix A.; Perez-Perez M.J.; Balzarini J.; De Clercq E.; Camarasa M.J.

Further Insights Into The Role of The Thymine Moiety of TSAO-T in The HIV-1 RT Inhibition
pp. 53-53(1)
Authors: Camarasa M.J.; Chamorro C.; Alvarez R.; Jimeno M.L.; Perez C.; Gago F.; Balzarini J.; De Clercq E.; San-Felix A.

A pyrido [1,2a] indole derivative identified as a novel non-nucleoside reverse transcriptase inhibitor of HIV-1
pp. 53-53(1)
Authors: Taylor D.L.; Ahmed P.S.; Tyms A.S.; Bedard J.; Duchaine J.; Falardeau G.; Lavallee J.F.; Hamel M.; Rando R.F.; Bowlin T.

Antiviral Properties of the Nonnucleoside Reverse Transcriptase Inhibitor UC781
pp. 53-53(1)
Authors: Buckheit R.W.; Fliakas-Boltz V.; Kinjerski T.L.; Russell J.D.; Pallansch L.A.

Antiviral Activity Profiling of the Furopyridine-thiopyrimidine, PNU-142721: a Novel, Potent, HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor
pp. 54-54(1)
Authors: Olmsted R.A.; Kopta L.A.; Wishka D.G.; Murphy M.J.; Schlachter S.T.; Nugent R.A.; Morris J.

Binding of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors to Human Serum Albumin and Human ₁Acid Glycoprotein : Conflicting Results Depending on the Assay Used
pp. 54-54(1)
Authors: de Bethune M.-P.; Andries K.; Azijn H.; Van Peel J.; Pauwels R.

Pentafuside (T20), A Novel Inhibitor of HIV-1 Fusion and Infection, is Synergistic When Used in Combination with Reverse Transcriptase (RT) and Protease Inhibitors in vitro
pp. 54-54(1)
Authors: Barney S.; Guthrie K.; Davis D.; Hopkins S.; Johnson M.R.; Lambert D.M.

In vitro synergy studies with MKC-442, a non-nucleoside HIV-1 reverse transcriptase inhibitor
pp. 54-54(1)
Authors: Hill E.; Taylor N.; Borroto-Esoda K.; Furman P.; Moxham C.; Painter G.

Synthesis and SAR Studies of Urea PETT Compounds Leading to the PETT-4 Series, Highly Potent Allosteric HIV-1 RT inhibitors
pp. 55-55(1)
Authors: Sahlberg C.; &unknown;9hgren C.; Ekelof K.; Engelhardt P.; Hogberg M.; Johansson N.G.; Kangasmetsa J.; Noreen R.; Oberg B.; Rydergard C.; Vrang L.; Zhang H.

Anti-HIV Activity of PETT-4 In vitro
pp. 55-55(1)
Authors: Vrang L.; &unknown;9hgren C.; Ekelof K.; Engelhardt P.; Hogberg M.; Noreen R.; Oberg B.; Rydergard C.; Sahlberg C.

Antiviral Effect of PETT-4 Compounds in Monkeys Infected with SHIV
pp. 55-55(1)
Authors: Bottiger D.; &unknown;9hgren C.; Benthin R.; Hogberg M.; Oberg B.; Sahlberg C.; Sahlberg B.-L.; Rydergard C.; Uberla K.

Acridone derivatives are transcriptional inhibitors of human immunodeficiency virus type 1 (HIV-1)
pp. 55-55(1)
Authors: Fujiwara M.; Okamoto M.; Watanabe M.; Machida H.; Shigeta S.; Konno K.; Yokota T.; Baba M.

RD6-Y664, Benzylhydroxylamine derivative, inhibits the replication of human immunodeficiency virus
pp. 56-56(1)
Authors: Okamoto M.; Fujiwara M.; Yamamoto O.; Shigeta S.; Konno K.; Yokota T.; Baba M.

Fluoroquinoline Derivatives as Potent Inhibitors of HIV-1 Replication and Cytokine Production
pp. 56-56(1)
Authors: Baba M.; Okamoto M.; Kawamura M.; Makino M.; Kimura Y.; Ikeuchi T.; Tetsuka T.; Okamoto T.

Structural Analogue of Calanolide A. Synthesis of 11-Demethyl-Calanolide A and its Anti-HIV Activities
pp. 56-56(1)
Authors: Lin W.; Zhou C.-M.; Zhao Z.-Z.; Xing Q.Z.; Chen X.-H.; Chen H.-S.

Cyclic Urea and Sulfamide-based Inhibitors of HIV-1 Protease. Changes in Binding Mode upon Modifications in the P1/P1&unknown; Side Chain
pp. 56-56(1)
Authors: Backbro K.; Andersson H.; Bonham N.M.; Classon B.; Danielson H.; Hallberg A.; Hulten J.; Karlen A.; Lowgren S.; Nillroth U.; Schaal W.; Unge T.

Cyclic 7-membered Sulfamide HIV-1 Protease Inhibitors
pp. 57-57(1)
Authors: Hulten J.; Schaal W.; Unge T.; Danielson U.H.; Classon B.; Samuelsson B.; Karlen A.; Hallberg A.

Evaluation of the Effects of Protease Inhibitors on the Replication of Simian Immunodeficiency Viruses (SIV) In Vitro
pp. 57-57(1)
Authors: Owens R.J.; Osterling M.C.; Lewis M.G.; Black R.J.; Buckheit R.W.

Efficacy of 9-(2-Phosphonylmethoxypropyl) Adenine for Therapy of Acute Feline Immunodeficiency Virus Infection
pp. 57-57(1)
Authors: Hoover E.A.; Myles M.H.; Ebner J.P.; Black R.J.; Bischofberger N.

Curcumin-like derivatives with potent activity against HIV-1 integrase: synthesis, biological evaluation and molecular modeling
pp. 57-57(1)
Authors: La Colla P.; Tramontano E.; Musiu C.; Marongiu M.; Novellino E.; Greco G.; Massa S.; Di Santo R.; Costi R.; Marino A.

Antiretroviral Activity of TCN-P in HIV-infected Human Macrophages
pp. 58-58(1)
Authors: Nassiri M.R.; Achim C.L.; Martinez A.J.; Wiley C.A.; Drach J.C.; Townsend L.B.

Inhibition of human immunodeficiency virus type-1 in macrophages by calcium trinatrium diethylene-triaminepentaacetic acid
pp. 58-58(1)
Authors: Groschel B.; Cinatl J.; von Briesen H.; Rabenau H.; Cinatl J.; Doerr H.W.

New Types of Anti-HIV Agents Identified by the NCI Drug Discovery Program
pp. 58-58(1)
Authors: Rice W.G.; Turpin J.A.; Huang M.; Howard O.M.Z.; Michejda C.J.; Bader J.P.

Novel Ribonucleotide Reductase (RR) Inhibitors, Didox and Trimidox, Produce Antiretroviral Effects in the Murine Immunodeficiency (MAIDS) and in the HIV-infected HuPBMC SCID Models.
pp. 58-58(1)
Authors: Elford H.; van't Riet B.; Mayhew C.; Oakley O.; Piper J.; Gallicchio V.; Black P.; Kunder S.; Goldberg G.; Broud D.; Hall B.; Bacho M.; Papermaster S.; Ussery M.

Immunomodulating and Antiviral effects of CNBA-Na on Isolated Human PBMC and HIV-Infected HuPBMC-SCID Mice
pp. 59-59(1)
Authors: Kinchington D.; Ayuko W.O.; Devine D.; Gilbert N.; Wood O.; Kunder S.; Broud D.; Papermaster S.; Bacho M.; Hall B.; Nielson C.; Ussery M.

Quantitative Structure-Activity Relationship Studies of Potential Anti-HIV Drugs
pp. 59-59(1)
Authors: Tsai C.C.; Lesniewski M.L.; Parakulam R.R.

Anti-HIV activity of polyoxometalates
pp. 59-59(1)
Authors: Witvrouw M.; Weigold H.; Marcuccio S.M.; Schols D.; Desmyter J.; De Clercq E.; Holan G.

In vitro anti-HIV activity of extract from Stevia rebaudiana
pp. 59-59(1)
Authors: Takahashi K.; Iwata Y.; Mori S.; Shigeta S.

Anti-HIV-1 Activity of a Commonly used Chinese Traditional Herb DS in vitro and in vivo
pp. 60-60(1)
Authors: Chen H.-S.; Zhang X.-Q.; Li T.; Lu Y.-Z.; Wu X.-X.; Chen X.-H.; Yan X.-G.

Role of cytolytic T-cells in controlling disease progression in a long-term nonprogressor (LTNP)
pp. 60-60(1)
Authors: Leschonsky B.; Kaufmann F.; Wolf H.; Harrer T.; Walker B.; Wagner R.

Novel Pharmaceutical Formulations With Virucidal Activity
pp. 60-60(1)
Authors: Thormar H.; Kristmundsdottir T.; Witvrouw M.; De Clercq E.

Development of Genotypic and Phenotypic Resistance to MKC-442, a Potent and Selective Inhibitor of HIV-1 Replication
pp. 60-60(1)
Authors: Harris J.; Borroto-Esoda K.; Hill E.; Moxham C.; Rousseau F.; McCreedy B.

Antiviral Susceptibilities of HIV-1 Reverse Transcriptase Recombinant Viruses Derived from AIDS Patients after Extended Adefovir Dipivoxil Therapy
pp. 61-61(1)
Authors: Miller M.D.; Anton K.E.; Mulato A.S.; Lamy P.D.; Cherrington J.M.

HIV-1 Reverse Transcriptase (RT) Expressing a K70E Mutation Exhibits a Decrease in Both Specific Activity and Processivity
pp. 61-61(1)
Authors: Lamy P.D.; Miller M.D.; Fuller M.D.; Mulato A.S.; Margot N.A.; Cihlar T.; Cherrington J.M.

Resistance to Loviride (R089439) and Other NNRTIs : Characterization of the In Vitro Emerging HIV-1 Variants under Continuous Pressure of the Inhibitors
pp. 61-61(1)
Authors: de Bethune M.-P.; Andries K.; Azijn H.; Van Peel J.; Pauwels R.

Genotypic Analysis and Phenotypic Susceptibility of HIV-1 Isolates from Patients Treated with Stavudine (d4T)-Didanosine (ddI) Combination
pp. 61-61(1)
Authors: Auger S.; Ferre-Aubineau V.; Monpeho S.; Reliquet V.; Billaudel S.; Raffi F.

Resistance Profile, Selectivity and Cellular Uptake Studies of BCH-10618, BCH-10619 and BCH-10652
pp. 62-62(1)
Authors: Mansour T.; Wainberg M.; Salomon H.; Quan Y.; Gourdeau H.; Richard A.; King C.; Nguyen-Ba N.; Rej R.; Bedard J.; Rando R.; Fortier C.; Proulx L.; Williams P.; Clement J.; Bowlin T.

Effect of Drug Resistance Engendering Mutations on Viral Fitness
pp. 62-62(1)
Authors: Stup T.L.; Pallansch L.A.; Buckheit R.W.

Evaluation of Anti-HIV Activity Against Low Passage Clinical Strains of HIV-1
pp. 62-62(1)
Authors: Osterling M.C.; Halliday S.M.; Buckheit R.W.

Potentiation of HIV-1 replication and failure of anti-HIV-1 activity of antiretroviral agents in cisplatin resistant cell line
pp. 62-62(1)
Authors: Kotchetkov R.; Groschel B.; Rabenau H.; Cinatl J.; Doerr H.W.; Cinatl J.

Treatment of HIV-infected cell cultures with high concentrations of anti-HIV drugs for several days does not prevent resumption of virus production upon removal of the antivirals
pp. 63-63(1)
Authors: Witvrouw M.; Andries K.; Pannecouque C.; Desmyter J.; De Clercq E.

cyclosal-Nucleotides of 2&unknown;,3&unknown;-dideoxy-adenosine derivatives as efficient nucleotide delivery systems
pp. 63-63(1)
Authors: Meier C.; Knispel T.; Marquez V.; De Clercq E.; Balzarini J.

Incorporation of Amphotericin B into Stealth Liposomes or Colloidal Dispersions Diminishes its In Vitro Anti-HIV Activity
pp. 63-63(1)
Authors: Konopka K.; Guo L.S.S.; Duzgunes N.

Comparison of the Plasma Pharmacokinetics of AZT and AZT Phosphoramidates
pp. 63-63(1)
Authors: Wagner C.R.; McIntee E.J.; Song H.; Zimmerman C.L.

Measurement of Intracellular Pools of dATP by High-Performance Liquid Chromatography Following Derivatization to Generate a Fluorescent Chromophore
pp. 64-64(1)
Authors: Zhang H.; Wood O.L.; Hall B.; Ciavarella T.B.; Nielsen C.J.; Ussery M.A.

The Intracellular Pharmacology of -L-ddA is Responsible for the Lack of Potent Anti-HIV Activity
pp. 64-64(1)
Authors: Placidi L.; Perigaud C.; Cretton-Scott E.; Gosselin G.; Pierra C.; Schinazi R.F.; Imbach J.L.; Sommadossi J.P.

Pre-clinical Pharmacology of -L-2&unknown;,3&unknown;-Dideoxy-5-Fluoro-Cytidine and its Prodrug Bis-[(t-butyl)SATE]--L-2&unknown;,3&unknown;-Dideoxy-5-Fluorocytidine Monophosphate
pp. 64-64(1)
Authors: Martin L.T.; Faraj A.; Schinazi R.F.; Imbach J.-L.; Gosselin G.; McClure H.M.; Sommadossi J.P.

Pharmacokinetics of 2&unknown;,3&unknown;-Dideoxy-3&unknown;-Fluoro-Guanosine (FLG) in Cynomolgus Monkeys and Rats
pp. 64-64(1)
Authors: Bottiger D.; Benthin R.; Borg N.; Johansson N.-G.; Linden K.; Oberg B.; Stahle L.; Zhou X.-X.

Studies of FLG as a Potent and Selective Inhibitor of Hepatitis B Virus Replication in vitro and in vivo
pp. 65-65(1)
Authors: Harmenberg J.; Ageland H.; Borg N.; Bottiger D.; Johansson N.-G.; Lofgren B.; Oberg B.; Pelcman M.; Schroder I.; Stahle L.; Vrang L.; Zhang H.; Zhou X.-X.

Anti-DHBV and -SIV Activity of 2&unknown;,3&unknown;-Dideoxy-3&unknown;-Fluoro-Guanosine (FLG) in vivo
pp. 65-65(1)
Authors: Ageland H.; &unknown;9hgren C.; Benthin R.; Bottiger D.; Johansson N.-G.; Lofgren B.; Oberg B.; Pelcman M.; Rydergard C.; Schroder I.; Zhou X.-X.

Anti-Hepatitis B Virus Activity of 3-Hexadecyloxypropane-1-phospho-penciclovir and 3-Hexadecyloxypropane-1-phospho-dideoxyguanosine in 2.2.15 Cells
pp. 65-65(1)
Authors: Kini G.D.; Beadle J.R.; Aldern K.A.; Richman D.D.; Korba B.E.; Hostetler K.Y.

Phospholipid Prodrugs of Antiviral Nucleosides: Efficacy of Orally Administered 3-Hexadecyloxypropane-1-phospho-acyclovir Against Hepatitis B Infection in Woodchucks
pp. 65-65(1)
Authors: Beadle J.R.; Kini G.D.; Korba B.E.; Tennant B.C.; Hostetler K.Y.

DAPD: A Novel Inhibitor of Hepatitis B Virus Replication
pp. 66-66(1)
Authors: Kiefer L.L.; Schinazi R.F.; Korba B.; Chu C.K.; Tennant B.; Hill E.L.; Begley J.; Lampert B.; Locarnini S.; Raig W.; Borroto-Esoda K.; Painter G.R.; Furman P.A.

Inhibition of DHBV DNA Replication with Antisense Oligodeoxynucleotides in Vitro and in Vivo
pp. 66-66(1)
Authors: Tao P.; Dong B.; Shao X.

Development of a Moderate Throughput Assay Using TaqMan PCR Technology to Identify Inhibitors of Hepatitis B Virus
pp. 66-66(1)
Authors: Halliday S.M.; Pallansch L.A.; Buckheit R.W.

Mutations in Human Hepatitis B Virus Polymerase Associated with Resistance to Lamivudine and Famciclovir Do Not Decrease Sensitivity to Adefovir
pp. 66-66(1)
Authors: Xiong X.; Flores C.; Yang H.; Westland C.E.; Toole J.J.; Gibbs C.S.

Selection of Woodchuck Hepatitis Virus Resistant to 3TC due to a Mutation in the Highly Conserved Polymerase FLLA Region in a Lifetime Woodchuck Antiviral Trial
pp. 67-67(1)
Authors: Schinazi R.F.; Stang H.L.; Tatti K.M.; Korba B.E.; Peek S.; Tennant B.C.

Effects of HPMPC on Inhibition of HPV-16 Transformed Cell Proliferation
pp. 67-67(1)
Authors: Johnson J.A.; Gangemi J.D.

Regulation by Human Papillomavirus E2 Proteins and Applications to Antiviral Drug Discovery
pp. 67-67(1)
Authors: Kovelman R.; Bilter G.K.; Glezer E.; Roman A.; Brown D.R.; Barbosa M.S.

Effect of Acyclic Nucleoside Phosphonates (ANPs) on the Proliferation of Adenovirus-transformed Cell Lines as Compared to Human Papillomavirus (HPV)-harboring Cell Lines
pp. 67-67(1)
Authors: Snoeck R.; Andrei G.; De Clercq E.

Inhibition of Human Cytomegalovirus Protease N_o with Monocyclic -Lactams
pp. 68-68(1)
Authors: Deziel R.; Malenfant E.

Discovery of A Novel Class of Potent Heterocyclic Human Cytomegalovirus Inhibitors and Their Structure-Activity Relationship Studies
pp. 68-68(1)
Authors: Jin H.; Chan L.; Stefanac T.; Wang W.; Lavallee J.-F.; Falardeau G.; Bedard J.; May S.; Yuen L.

The Furin-Directed ₁-Antitrypsin Variant ₁-PDX: A Potent New Anti-Cytomegalovirus Drug
pp. 69-69(1)
Authors: Jean F.; Thomas L.; Nelson J.; Thomas G.

Benzimidazole l-Sugar Nucleosides: Large Biological Changes from Small Structural Modifications
pp. 69-69(1)
Authors: Drach J.C.; Migawa M.T.; Girardet J.-L.; Ptak R.G.; Oh C.; Barnat S.; Walker J.A.; Devivar R.V.; Chamberlain S.D.; Koszalka G.W.; Underwood M.R.; Biron K.K.; Townsend L.B.

Phosphoralaninate prodrugs of methylenecyclo-propane analogues of nucleosides as antiviral agents
pp. 69-69(1)
Authors: Zemlicka J.; Qiu Y.-L.; Lin J.-S.; Cheng Y.-C.; Ptak R.G.; Breitenbach J.M.; Drach J.C.; Kern E.R.

Inhibition of Human Cytomegalovirus Replication in SCID-hu Retinal Tissue Implants by Ganciclovir and Cidofovir
pp. 69-69(1)
Authors: Bidanset D.J.; Rybak R.J.; Hartline C.B.; Kern E.R.

Mutations Occur in Highly Conserved Domains of Murine Cytomegalovirus DNA Polymerase in Cidofovir- and Lobucavir-resistant Strains
pp. 70-70(1)
Authors: Tatti K.M.; Stang H.; Barnard D.; Smee D.; Schinazi R.F.

Pharmacokinetics and Efficacy of AV-038, an Oral Prodrug of a Novel Potent Antiherpetic Nucleoside Analogue A-5021
pp. 70-70(1)
Authors: Iwayama S.; Suzuki K.; Nakagawa T.; Sekiyama T.; Ohnishi T.; Ohmura Y.; Ono N.; Nakazawa H.; Ikemura O.; Tsuji T.; Okunishi M.

In Vivo Anti-CMV Activity and Safety of Oral 1263W94 in HIV-Infected Subjects with Asymptomatic CMV Shedding
pp. 70-70(1)
Authors: Drew W.; Lalezari J.; Wang L.; Miner R.; Aberg J.; Wire M.; Jacobson M.

Synthesis and Activity of a New Series of C₃-Aza Carbocyclic Influenza Neuraminidase Inhibitors
pp. 70-70(1)
Authors: Lew W.; Wu H.W.; Mendel D.B.; Tai C.Y.; Escarpe P.A.; Kim C.U.; Laver W.G.; Graves B.J.

Lack of In Vivo Development of Influenza A Virus Resistance to the Orally Effective Neuraminidase Inhibitor GS4104
pp. 71-71(1)
Authors: Sidwell R.W.; Bailey K.W.; Wong M.H.; Huffman J.H.

In Vitro Selection and Characterization of a Human Influenza Virus With Decreased Susceptibility to GS 4071
pp. 71-71(1)
Authors: Mendel D.B.; Tai C.Y.; Escarpe P.A.

Chemoprophylaxis of influenza A infections in mice and ferrets with neuraminidase inhibitors, exemplified by zanamivir (GC167)
pp. 72-72(1)
Authors: Fenton R.J.; Owens I.J.; Morley P.J.

Potent Inhibition Of Respiratory Syncytial Viruses (RSV) By A 2-5A-Antisense Oligonucleotide Chimera Targeted To Intragenic Signals In The RSV Genome
pp. 72-72(1)
Authors: Barnard D.L.; Sidwell R.W.; Matheson J.E.; Player M.; Torrence P.F.

PCR amplification and determination of the RNA sequences for the P3 coding region of Human Rhinoviral serotypes
pp. 72-72(1)
Authors: Meador J.W.; Ngo H.; Ford C.E.; Patick A.K.; Ferre R.A.; Matthews D.A.; Worland S.T.

Recombinant human interferon-alpha hybrid B/D protects mice against lethal Ebola virus infection
pp. 72-72(1)
Authors: Bray M.; Gangemi D.; Thompson E.; Huggins J.W.

Cidofovir (HPMPC) Treatment of Monkeypox
pp. 73-73(1)
Authors: Huggins J.W.; Smee D.; Martinez M.J.; Bray M.

Biological activities of 9-(2-phosphonylmethoxyethyl)-N⁶-cyclopropyl-2,6-diaminopurine
pp. 74-74(1)
Authors: Naesens L.; Hatse S.; Andrei G.; Balzarini J.; Neyts J.; Snoeck R.; De Clercq E.

Anti-herpes Activities of 2-Thio-pyrimidine Nucleoside Analogs; Structure and Activity Relationship
pp. 74-74(1)
Authors: Shigeta S.; Mori S.; Kira T.; Saneyoshi M.

Chemistry and properties of cycloSaligenyl-nucleotides (cycloSal-NMP) of acyclic nucleoside analogues as potential anti-HSV agents
pp. 75-75(1)
Authors: Meier C.; Habel L.; Haller F.; Wutzler P.

Mechanism of anti-herpesvirus activity of natural carrageenans of diverse structural types
pp. 75-75(1)
Authors: Damonte E.B.; Carlucci M.J.; Ciancia M.; Matulewicz M.C.; Cerezo A.S.

Antiviral Activity of New Piperazinylpyrimidine Derivates
pp. 75-75(1)
Authors: Pancheva S.N.; Konstantinova R.; Remichkova M.; Roeva I.

Synthesis and Antiviral Activity of 6-Chloropurine Arabinosides
pp. 75-75(1)
Authors: Maruyama T.; Sato Y.; Oto Y.; De Clercq E.

A New Prodrug Concept for Nucleoside Analogs
pp. 76-76(1)
Authors: Johansson N.G.; Engelhardt P.; Hogberg M.; Lindborg B.; Linden K.; Stahle L.; Zhou X.-X.

Development of New Prodrugs of (-)-9-[4-Hydroxy-2-(hydroxymethyl)butyl]guanine (H2G)
pp. 76-76(1)
Authors: Engelhardt P.; Hogberg M.; Johansson N.G.; Lindborg B.; Linden K.; Sahlberg C.; Stahle L.; Zhou X.-X.

Inhibition of the growth of herpes simplex virus type 2 by vaccinia virions
pp. 76-76(1)
Authors: Katz E.; Keywan K.

Inhibitory effect of cycloSaligenyl-Nucleoside Monophosphates (cycloSal-NMP) of Acyclic Nucleoside Analogues on HSV-1 and EBV
pp. 76-76(1)
Authors: Meerbach A.; Klocking R.; Meier C.; Wutzler P.

Interference of zinc with pentosan polysulfate in the HSV-1/Vero cell system
pp. 77-77(1)
Authors: Klocking R.; John B.; Knispel A.; Helbig B.; Wutzler P.

Application of Antiviral and Local Anaesthetics or Anti-inflammatory Agents for the Topical Treatment of Herpes Simplex Virus Assessed Using a Murine Zosteriform Infection Model
pp. 77-77(1)
Authors: Awan A.R.; Harmenberg J.; Field H.J.

The Effects of a Topical Serine-protease (PHM-101) on HSV-1 Pathogenesis Assessed in a Murine Neck-ear Zosteriform Infection Model for the Disease
pp. 77-77(1)
Authors: Awan A.R.; Field H.J.; Shilton T.S.; Wild R.N.

A HSV helicase-primase inhibitor, BILS 45 BS, with potent oral activity against acyclovir-resistant infection in nude mice
pp. 77-77(1)
Authors: Duan J.; Liuzzi M.; Paris W.; Liard F.; Browne A.; Cordingley M.G.

Mycophenolate Mofetil Ointment Potentiates the Activity of Systemically Administered Acyclovir in Murine Models for Cutaneous Herpesvirus Infection
pp. 78-78(1)
Authors: Neyts J.; Andrei G.; De Clercq E.

Denavir, Zovirax Cream and Zovirax Ointment in the Topical Treatment of Experimental Dorsal Cutaneous Herpes Simplex Virus Type 1 (HSV-1) Infection in the Guinea Pig
pp. 78-78(1)
Authors: McKeough M.; Spruance S.

Famciclovir treatment of acute herpes simplex virus infection in mice reduces the subsequent frequency of latent virus reactivation induced by transitory hyperthermia
pp. 78-78(1)
Authors: Sutton D.; Kingsley S.; Wells G.; Bartus H.; Esser K.

Antiviral activity of RD6-2198 against intravaginal infection with herpes simplex virus type 2 in mice
pp. 78-78(1)
Authors: Ashida N.; Okamoto M.; Fujiwara M.; Mizuta T.; Konno K.; Hanasaki Y.; Ide T.; Katsuura K.; Sawada H.; Shigeta S.; Yokota T.

Efficacy of Topical Acyclovir Monophosphate in Genital HSV-2 Infections of Guinea Pigs
pp. 79-79(1)
Authors: Palmer J.; Harden E.; Szczech G.; Painter G.; McLean S.; Hostetler K.Y.; Kern E.R.

In Vitro and In Vivo Evaluation of the Activity of Stannous Compounds Against Herpes Simplex Virus
pp. 79-79(1)
Authors: Reising S.; Bourne K.; Bourne N.; El-Awar F.; Pyles R.; Majetti S.; Stanberry L.

Evaluation of Triclosan as a Possible Intravaginal Microbicide: In Vitro and In Vivo Activity Against Herpes Simplex Virus Type 2 (HSV-2)
pp. 79-79(1)
Authors: Reising S.; Bourne K.; El-Awar F.; Bourne N.; Stanberry L.

Evaluation of Undecylenic acid as a topical microbicide against genital herpes infection in mice
pp. 79-79(1)
Authors: Bourne N.; Ireland J.; Bernstein D.

Pattern of Cross-Resistance between Phosphonylmethoxyethylguanine (PMEG) and Cyclopropylphosphonylmethoxyethyl-2,6-diaminopurine (CPr-PMEDAP) and Other Anti-Herpesvirus Agents
pp. 80-80(1)
Authors: Andrei G.; Snoeck R.; De Clercq E.

Characterization of Herpes Simplex Virus Type 1 (HSV-1) Mutants Arising After Multi-step Versus Single Round Selection with Foscarnet (PFA) and the Phosphonylmethoxyethyl (PME) Derivatives of Adenine (PMEA) and 2,6-Diaminopurine (PMEDAP)
pp. 80-80(1)
Authors: Andrei G.; Snoeck R.; De Clercq E.; Fiten P.; Opdenakker G.

Establishment of herpes simplex virus thymidine kinase expressing cell line and characterization of an acyclovir-resistant mutant by using it.
pp. 80-80(1)
Authors: Lee C.-K.; Kim J.H.; Paeng J.-W.; Kim H.S.; Park J.-B.

Phenotypic and genotypic characterisation of clinical isolates of herpes simplex virus resistant to acyclovir
pp. 80-80(1)
Authors: Snowden W.; Harris W.; Collins P.; Sowa M.; Fenton R.; Darby G.

In vitro susceptibility to Ganciclovir (GCV) and Foscarnet (PFA) in HIV infected patients: Correlation with therapeutic failure and CMV shedding after treatment
pp. 81-81(1)
Authors: Houhou-Fidouh N.; Cecille A.; Matheron S.; Simon M.; Salmon-Ceron D.; Leport C.; Brun-Vezinet F.

Plaque Autoradiography (PA) in Combination With Plaque Reduction Assay (PRA) for the Evaluation of Herpes Simplex Virus (HSV) Antiviral Resistance in a Clinical Trial
pp. 81-81(1)
Authors: Sacks S.; Crosson P.; Rennie B.

Similarities and differences in the genotoxic and apoptosis-inducing capacity of ganciclovir and penciclovir, respectively, in HSVtk⁺ transfectants of Chinese hamster ovary cells
pp. 81-81(1)
Authors: Thust R.; Klocking R.; Voutilainen N.; Wutzler P.; Kaina B.

Clinical Trials of Treatment of Meniere's Disease with ACV
pp. 81-81(1)
Author: Shichinohe M.

In Vitro Activity of Methylenecyclopropane Analogues of Nucleosides Against Cytomegalovirus Infections
pp. 82-82(1)
Authors: Hartline C.B.; Zemlicka J.; Qiu Y.-L.; Bidanset D.J.; Harden E.; Sommadossi J.-P.; Kern E.R.

Effective Treatment of Murine Cytomegalovirus Infections with Methylenecyclopropane Analogues of Nucleosides
pp. 82-82(1)
Authors: Rybak R.J.; Zemlicka J.; Qiu Y.-L.; Kern E.R.

CADA Compounds: Novel Chemotherapeutic Agents for the Human Cytomegalovirus (HCMV)
pp. 82-82(1)
Authors: Bell T.W.; Qi J.; Samala M.F.; van Geelen A.; St. Jeor S.C.

In Vitro Antiviral Effect of 2&unknown;-Fluoro-4&unknown;-thio-arabinofuranosyl Guanine and 2,6-Diaminopurine against Clinical Isolates of Human Cytomegarovirus
pp. 82-82(1)
Authors: Machida H.; Endo M.; Yamada K.; Yoshimura Y.; Ijichi O.; Eizuru Y.

Identification of Novel Nucleotide Tetrahydrofuranyl Phosphonate Analogues With Potent Anti-HCMV Activity
pp. 83-83(1)
Authors: Nguyen-Ba N.; Chan L.; Turcotte N.; Barbeau D.; Bedard J.; Yuen L.; Coates J.A.V.; Ryan M.; Sowa M.

Design and synthesis of a novel class of dioxolane nucleotide analogs with anti-HCMV activity
pp. 83-83(1)
Authors: Nguyen-Ba N.; Quimpere M.; Brown W.; Lee N.; Mitchell H.; Labine S.

Inhibition of Human Cytomegalovirus Proteinase by Salcomine Derivatives
pp. 83-83(1)
Authors: Watanabe S.; Konno K.; Shigeta S.; Yokota T.

Antiviral Activity of Lipid Prodrugs of Foscarnet and Ganciclovir Against the AD169 and Toledo Strains of Human Cytomegalovirus
pp. 83-83(1)
Authors: Aldern K.A.; Beadle J.R.; Kini G.D.; Stoddart C.A.; Hostetler K.Y.

Novel Inhibitors of Human Cytomegalovirus (HCMV) Cascade Gene Expression
pp. 84-84(1)
Authors: Wu J.; O'Neill J.; Barbosa M.S.

Inhibition of Proteinase Dependent Processing of the Scaffold Proteins of HCMV Capsid by Monocyclic -Lactams
pp. 84-84(1)
Authors: Lagace L.; Do F.; Malenfant E.; Deziel R.; Cordingley M.G.

Modulation of HCMV gene expression by isoquinolines
pp. 84-84(1)
Authors: Bedard J.; Copsey A.; Stamminger T.; Taylor D.L.; Tyms A.S.; Chan L.; Stefanac T.; Bowlin T.; Rando R.F.

Pharmacokinetic Studies of Naphthyridine Analog HCMV Inhibitors and Discovery of Substituted Isoquinoline Analogs as Metabolically Stable Anti-HCMV Agents
pp. 84-84(1)
Authors: Jin H.; Chan L.; Stefanac T.; Hu Z.; Yanmin C.; Belanger O.; Bedard J.; St-Pierre S.M.; St-Pierre A.

Antiviral agent glycyrrhizin stimulates human cytomegalovirus replication in retinal pigment epithelial cells
pp. 85-85(1)
Authors: Vogel J.-U.; Cinatl J.; Spielhofen A.; Kabickova H.; Doerr H.W.; Cinatl J.

Phenotypic Assay for Drug Susceptibility of Clinical Isolates of Human Cytomegalovirus (HCMV)
pp. 85-85(1)
Authors: McSharry J.; Lurain N.

A Point Mutation Within The CMV DNA Polymerase Confers Cross-Resistance to Foscarnet And Ganciclovir
pp. 85-85(1)
Authors: Mousavi-Jazi M.; Brytting M.; Sundqvist V.-A.

Novel Benzimidazole-Resistant Human Cytomegalovirus Isolates Identify a Third Mutation in the UL89 Open Reading Frame
pp. 85-85(1)
Authors: Krosky P.M.; Bigalke S.M.; Ptak R.G.; Murphy D.E.; Townsend L.B.; Drach J.C.

The Frame-Shift Mutation in UL97 Gene of a Clinical Isolate of Cytomegalovirus from an AIDS Patient
pp. 86-86(1)
Authors: Yoshito E.; Osamu I.

Exploring the Mechanism of Action of 2-Hydroxymethylcyclopropylidenemethyl Purines by Selection of Drug-Resistant Human Cytomegalovirus
pp. 86-86(1)
Authors: Drach J.C.; Breitenbach J.M.; Feng K.W.-H.; Jacobson J.G.; Qiu Y.-L.; Zemlicka J.

Utilization of Semen Titration to Assay In Vivo Antiviral Activity of Anti-CMV Drugs in Asymptomatic Subjects
pp. 86-86(1)
Authors: Drew W.; Miner R.; McMullen D.; Lalezari J.; Glutzer E.; Wang L.

Improved Method for the Detection of Ganciclovir in Plasma Using HPLC with Electrochemical Detection
pp. 86-86(1)
Authors: Gardner M.F.; Hostetler K.Y.

The Effect of Intraperitoneal Injection of 1-O-octadecyl-sn-Glycero-3-Foscarnet and its Carboxymethyl Ester on Mortality and Serum Calcium Levels in Mice
pp. 87-87(1)
Authors: Wright K.N.; Gardner M.F.; Beadle J.R.; Hostetler K.Y.

The Use of Electroretinography to Study MCMV Induced Retinitis in the SCID Mouse
pp. 87-87(1)
Authors: Garneau M.; Bolger G.T.; Bousquet C.; Kibler P.; Cordingley M.G.

Kinetic Studies of the Inhibition of Influenza Neuraminidases by GS 4071
pp. 87-87(1)
Authors: Mendel D.B.; Escarpe P.A.; Tai C.Y.; Williams M.A.; Lew W.; Wu H.; Kim C.U.; Laver G.; Graves B.J.

Synergistic In Vitro Anti-Influenza Virus Effects of the Neuraminidase Inhibitor GS4071 and Ribavirin
pp. 87-87(1)
Authors: Huffman J.H.; Morrison A.; Syndergaard T.; Sidwell R.W.

Activities of zanamivir (GG167) and GS4104 in a series of influenza A virus animal models
pp. 88-88(1)
Authors: Fenton R.J.; Owens I.J.; Morley P.J.; Bethell R.C.

In vitro and In vivo Inhibitary Activity of Influenza A virus by Phosphorothioate Oligodeoxynucleotides
pp. 88-88(1)
Authors: Wang S.; Chen Z.; Zhu B.; Sun Z.

Anti-influenza A virus activities of antisense phosphorothioate oligonucleotides in mice depend on presence of cationic liposome and route of administration
pp. 88-88(1)
Authors: Mizuta T.; Fujiwara M.; Yokota T.; Shigeta S.; Hatta T.; Abe T.; Takaku H.

Anti-influenza viral glycoprotein from the roots of Isatis tinctoria L
pp. 88-88(1)
Authors: Nagai T.; Yang J.-W.; Sakurai M.; Yamada H.

The Mechanism of Action of Arbidol Against Influenza Virus. Selection and Characterization of Arbidol-Resistant Mutants
pp. 89-89(1)
Authors: Leneva I.; Hay A.

In vitro combined apply of proteolytic inhibitors with unithiolum
pp. 89-89(1)
Authors: Lozitsky V.; Sudakov A.

Mechanism of specific inhibition on respiratory syncytial virus replication by benzoditiin compound, RD3-0028
pp. 89-89(1)
Authors: Sudo K.; Konno K.; Shigeta S.; Yokota T.

Potential of the IMP Dehydrogenase Inhibitors for Antiviral Therapies of Poxvirus Infections
pp. 89-89(1)
Authors: Smee D.F.; Huggins J.W.

A cyclic urea derivative (CU), an in vivo efficient inhibitor of flavivirus replication
pp. 90-90(1)
Authors: Galabov A.S.; Tsvetkov P.; Uzunov S.; Abashev Y.; Minkov V.; Wassilewa L.; Mukova L.; Davydova A.A.; Lazarenko A.A.; Barinsky I.F.

Glycyrrhizic acid as inhibitor of Marburg virus reproduction
pp. 90-90(1)
Authors: Pokrovsky A.G.; Belanov E.F.; Volkov G.N.

Fatty acid analogs as inhibitors of arenavirus replication
pp. 90-90(1)
Authors: Damonte E.B.; Cordo S.; Candurra N.A.

Cidofovir is a potent inhibitor of murine polyoma virus-induced hemangioma formation in rats
pp. 90-90(1)
Authors: Neyts J.; Liekens S.; Andrei G.; Vandeputte M.; De Clercq E.

In vitro infection with parvovirus B19
pp. 91-91(1)
Authors: Hemauer A.; Gigler A.; Gareus R.; Wolf H.; Modrow S.

Generation of Human Monoclonal Antibodies against Parvovirus B19
pp. 91-91(1)
Authors: Gigler A.; Dorsch S.; Hemauer A.; Zolla-Pazner S.; Wolf H.; Modrow S.; Gorny M.K.

Mutational Analysis of The RNA Involved In Ribosomal Frameshifting In Barley Yellow Dwarf Virus
pp. 91-91(1)
Authors: Sung D.; Kang H.

Application of Antisense and Ribozyme In Controlling The Viral Replication
pp. 91-91(1)
Authors: Kang H.; Sung D.

Capsid and RNA stabilisation of the Oral Polio Vaccine
pp. 92-92(1)
Authors: Vrijsen R.; Verheyden B.; Rombaut B.

Drug Discovery Assays for Hepatitis C Virus: Development of a High Throughput Assay for the NS3 RNA Helicase
pp. 93-93(1)
Authors: August E.M.; Patnaude L.; Perry K.; Davis D.v.; Yeh L.-A.